Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"). Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology, Haizi, China’s second largest inositol manufacturer, Natural Dailyhealth, a company engaged in the production and sales of plant extracts for use as key active ingredients in healthcare products, and Botai, a company engaged in the production and sales of collagen products. The Group employs more than 1,600 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment in Shenzhen. Update re Compulsory Acquisition 2021/01/11 Notice of Bye-law amendment approval and Complusory Conversion 2020/12/08 Notice of written resolution 2020/12/03 update re Listing Cancellation 2020/12/02 Compulsory Acquisition Notice 2020/12/02 Result of the Tender Offer 2020/11/11 Result of SGM and Notification of change to Shares 2020/11/03 Lansen's seventh share reduction plan of Starry 2020/11/03 Interim Report 2020 View | PDF Annual Report 2019 View | PDF Interim Report 2019 View | PDF Cathay International Holdings Limited. Copyright © 2010. All right reserved. Disclaimer